<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Genschmer KR</submitter><funding>BLRD VA</funding><funding>UAB Center for Free Radical Biology</funding><funding>UAB O’Brien Acute Kidney Injury Center</funding><funding>UAB Lung Health Center</funding><funding>Nancy Dunlap Chair</funding><funding>NIDDK NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>The Gregory Fleming James CF Center</funding><funding>Veteran’s Affairs</funding><funding>NIH</funding><funding>Comprehensive Cancer Center Core</funding><pagination>113-126.e15</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6368091</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>176(1-2)</volume><pubmed_abstract>Here, we describe a novel pathogenic entity, the activated PMN (polymorphonuclear leukocyte, i.e., neutrophil)-derived exosome. These CD63&lt;sup>+&lt;/sup>/CD66b&lt;sup>+&lt;/sup> nanovesicles acquire surface-bound neutrophil elastase (NE) during PMN degranulation, NE being oriented in a configuration resistant to α1-antitrypsin (α1AT). These exosomes bind and degrade extracellular matrix (ECM) via the integrin Mac-1 and NE, respectively, causing the hallmarks of chronic obstructive pulmonary disease (COPD). Due to both ECM targeting and α1AT resistance, exosomal NE is far more potent than free NE. Importantly, such PMN-derived exosomes exist in clinical specimens from subjects with COPD but not healthy controls and are capable of transferring a COPD-like phenotype from humans to mice in an NE-driven</pubmed_abstract><journal>Cell</journal><pubmed_title>Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung.</pubmed_title><pmcid>PMC6368091</pmcid><funding_grant_id>P30 CA031148</funding_grant_id><funding_grant_id>R01 HL102371</funding_grant_id><funding_grant_id>I01BX001756</funding_grant_id><funding_grant_id>R01 HL114439</funding_grant_id><funding_grant_id>R01 HL110950</funding_grant_id><funding_grant_id>R01 HL077783</funding_grant_id><funding_grant_id>I01 BX001756</funding_grant_id><funding_grant_id>R01HL126596</funding_grant_id><funding_grant_id>T32HL105346-07</funding_grant_id><funding_grant_id>T32 HL105346</funding_grant_id><funding_grant_id>R35HL135710</funding_grant_id><funding_grant_id>K08 HL123940</funding_grant_id><funding_grant_id>K08 HL141652</funding_grant_id><funding_grant_id>R01 HL126603</funding_grant_id><funding_grant_id>AHA-17SDG32720009</funding_grant_id><funding_grant_id>R01 HL126596</funding_grant_id><funding_grant_id>P30 DK079337</funding_grant_id><funding_grant_id>R01HL114439</funding_grant_id><funding_grant_id>P30 DK072482</funding_grant_id><funding_grant_id>R01HL077783</funding_grant_id><funding_grant_id>R01HL110950</funding_grant_id><funding_grant_id>T32 HL105346-05</funding_grant_id><funding_grant_id>R01HL102371</funding_grant_id><funding_grant_id>K08HL123940</funding_grant_id><funding_grant_id>R01HL126603</funding_grant_id><funding_grant_id>R35 HL135710</funding_grant_id><pubmed_authors>McNicholas CM</pubmed_authors><pubmed_authors>Gaggar A</pubmed_authors><pubmed_authors>Szul T</pubmed_authors><pubmed_authors>Viera L</pubmed_authors><pubmed_authors>Dobosh BS</pubmed_authors><pubmed_authors>Bratcher PE</pubmed_authors><pubmed_authors>Abdalla TH</pubmed_authors><pubmed_authors>Tirouvanziam R</pubmed_authors><pubmed_authors>Lal C</pubmed_authors><pubmed_authors>Rezonzew G</pubmed_authors><pubmed_authors>Russell DW</pubmed_authors><pubmed_authors>Noerager BD</pubmed_authors><pubmed_authors>Abdul Roda M</pubmed_authors><pubmed_authors>King RW</pubmed_authors><pubmed_authors>Wells JM</pubmed_authors><pubmed_authors>Margaroli C</pubmed_authors><pubmed_authors>Blalock JE</pubmed_authors><pubmed_authors>Dransfield MT</pubmed_authors><pubmed_authors>Genschmer KR</pubmed_authors><pubmed_authors>Xu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung.</name><description>Here, we describe a novel pathogenic entity, the activated PMN (polymorphonuclear leukocyte, i.e., neutrophil)-derived exosome. These CD63&lt;sup>+&lt;/sup>/CD66b&lt;sup>+&lt;/sup> nanovesicles acquire surface-bound neutrophil elastase (NE) during PMN degranulation, NE being oriented in a configuration resistant to α1-antitrypsin (α1AT). These exosomes bind and degrade extracellular matrix (ECM) via the integrin Mac-1 and NE, respectively, causing the hallmarks of chronic obstructive pulmonary disease (COPD). Due to both ECM targeting and α1AT resistance, exosomal NE is far more potent than free NE. Importantly, such PMN-derived exosomes exist in clinical specimens from subjects with COPD but not healthy controls and are capable of transferring a COPD-like phenotype from humans to mice in an NE-driven</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jan</publication><modification>2026-04-14T21:17:52.271Z</modification><creation>2020-05-22T07:35:33Z</creation></dates><accession>S-EPMC6368091</accession><cross_references><pubmed>30633902</pubmed><doi>10.1016/j.cell.2018.12.002</doi></cross_references></HashMap>